Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Hematol Oncol Clin North Am. 2017 Apr;31(2):317–334. doi: 10.1016/j.hoc.2016.11.006

TABLE 10.

Treatment of pcALCL

Solitary or grouped lesions Local radiotherapy, first line
Excision
Multifocal Low dose methotrexate (5–25mg/week)
Systemic retinoids
Pralatrexate
Brentuximab vedotin
Monitor for spontaneous resolution
Extracutaneous spread Nodal radiation, if single basin
Brentuximab vedotin
Low dose methotrexate (5–25mg/week)
Pralatrexate
Multi-agent doxorubicin based chemotherapy

Data from National Comprehensive Cancer Network. Non-Hodgkin lymphomas version 3.2016 (https://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf).